Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meyling Cheok

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
Blood|November 19, 2016
Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromesVirginie Chesnais, Marie-Laure Arcangeli, Caroline Delette, et al.
Blood Advances|May 19, 2023
LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA studyLoïc Vasseur, Laurène Fenwarth, Jérôme Lambert, et al.
American Journal of Hematology|March 6, 2013
Neurofibromatosis-1 gene deletions and mutations in de novo adult acute myeloid leukemiaElise Boudry-Labis, Catherine Roche-Lestienne, Olivier Nibourel, et al.
Blood|May 22, 2010
Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remissionOlivier Nibourel, Olivier Kosmider, Meyling Cheok, et al.
Blood|December 28, 2019
Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemiaElise Fournier, Nicolas Duployez, Benoît Ducourneau, et al.
Nature Medicine|September 28, 2011
Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cellsBarthelemy Diouf, Qing Cheng, Natalia F Krynetskaia, et al.
Oncotarget|October 22, 2015
IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French AssociationHouria Debarri, Delphine Lebon, Christophe Roumier, et al.
Leukemia|October 7, 2021
Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AMLMatthieu Duchmann, Orianne Wagner-Ballon, Thomas Boyer, et al.
Leukemia|August 10, 2018
The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemiaNicolas Duployez, Alice Marceau-Renaut, Céline Villenet, et al.
Oncotarget|August 19, 2015
Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML)Aminetou Mint Mohamed, Marie Balsat, Morgan Thenoz, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Blood|November 19, 2016
Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromesVirginie Chesnais, Marie-Laure Arcangeli, Caroline Delette, et al.
Blood Advances|May 19, 2023
LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA studyLoïc Vasseur, Laurène Fenwarth, Jérôme Lambert, et al.
American Journal of Hematology|March 6, 2013
Neurofibromatosis-1 gene deletions and mutations in de novo adult acute myeloid leukemiaElise Boudry-Labis, Catherine Roche-Lestienne, Olivier Nibourel, et al.
Blood|May 22, 2010
Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remissionOlivier Nibourel, Olivier Kosmider, Meyling Cheok, et al.
Blood|December 28, 2019
Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemiaElise Fournier, Nicolas Duployez, Benoît Ducourneau, et al.
Nature Medicine|September 28, 2011
Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cellsBarthelemy Diouf, Qing Cheng, Natalia F Krynetskaia, et al.
Oncotarget|October 22, 2015
IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French AssociationHouria Debarri, Delphine Lebon, Christophe Roumier, et al.
Leukemia|October 7, 2021
Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AMLMatthieu Duchmann, Orianne Wagner-Ballon, Thomas Boyer, et al.
Leukemia|August 10, 2018
The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemiaNicolas Duployez, Alice Marceau-Renaut, Céline Villenet, et al.
Oncotarget|August 19, 2015
Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML)Aminetou Mint Mohamed, Marie Balsat, Morgan Thenoz, et al.
Pageof 5